Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic s Q4 Revenues Soar on Sales of DNA Analysis Product

NEW YORK, Jan 31 – Based on increased sales of its genomic mutation analysis tools, Omaha, Neb.-based Transgenomic reported increased revenues for the fourth quarter Wednesday, while losses decreased and expenses held steady.

The company reported fourth quarter revenues of $7.1 million, up 63 percent from revenues of $4.3 million in the third quarter of 1999.

" During the quarter approximately 20 percent of the units sold specifically for variation detection applications went to existing customers,” Collin D’Silva, Transgenomic CEO said in a statement. “In addition, strong fourth quarter sales to commercial accounts helped that category represent approximately 25 percent of total installations for the year. These results demonstrate our success with utilizing a single platform to provide solutions for multiple applications."

Total operating expenses for the quarter came to $5 million, including $3.7 million for sales and administrative costs, and $2 million for R&D. The company's expenses last year were substantially similar, although sales and administrative costs increased by $700,000 from the year-ago quarter.

Transgenomic’s fourth quarter losses totaled $374,000, or two cents per share, a figure that took into account a net gain of $604,000 from the sale of the company’s non-life sciences product line in March 2000. These losses beat Wall Street’s expectations by four cents per share, based on a survey of two brokers by FirstCall/Thomson Financial.

The three year-old company, which completed its Initial Public Offering in July 2000, produces and markets the Wave System, which is designed to identify DNA mutations using micro-bead technology. The product packs micro-beads, each of which has a proprietary surface chemistry that interacts with DNA molecules, into a DNA separation column. The product than uses liquid reagents to separate out the molecules, and the analysis is performed using the company’s bioinformatics Wavemaker software.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.